Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
NCT02837575 is registered in ClinicalTrials.gov with Vical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
- Lead sponsor
- Vical
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2016
- Completion date
- December 31, 2018
- Enrollment
- 261 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.